CRISPR Therapeutics (CRSP) Misses Q2 EPS by 6c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($1.49), $0.06 worse than the analyst estimate of ($1.43).

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Canadian trade officials to meet U.S. counterparts in Washington Monday
• Roblox user data suggests bookings above guidance range